{
    "nctId": "NCT05916755",
    "briefTitle": "Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform",
    "officialTitle": "Identification of Predictive Biomarkers of Response to Chemotherapy and Immune Checkpoint Inhibitors in Early Triple Negative Breast Cancer: an Integrative Multiomics Platform",
    "overallStatus": "RECRUITING",
    "conditions": "Triple Negative Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Pathologic complete response (pCR) rate at definitive surgery",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically documented TNBC (negative human epidermal growth factor receptor 2 \\[HER2\\], estrogen receptor \\[ER\\], and progesterone receptor \\[PgR\\] status)\n* Stage 2 - 3 defined by the American Joint Committee of Cancer (AJCC) staging criteria 8th edition for breast cancer as assessed by the investigator based on radiological and/or clinical assessment\n* Patient is a candidate to receive NACT with or without ICI as assessed by the investigator\n* Patient is \u2265 18 years old at the time of consent to participate in this trial\n\nExclusion Criteria:\n\n* Metastatic disease on imaging (stage 4)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}